[go: up one dir, main page]

UY37927A - Proceso para la preparación de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo - Google Patents

Proceso para la preparación de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo

Info

Publication number
UY37927A
UY37927A UY0001037927A UY37927A UY37927A UY 37927 A UY37927 A UY 37927A UY 0001037927 A UY0001037927 A UY 0001037927A UY 37927 A UY37927 A UY 37927A UY 37927 A UY37927 A UY 37927A
Authority
UY
Uruguay
Prior art keywords
methylpropoxi
metoxipiridin
piridina
diazabiciclo
pirazolo
Prior art date
Application number
UY0001037927A
Other languages
English (en)
Inventor
Andrew T Metcalf
Gabrielle R Kolakowski
Charles Todd Eary
Stacey Spencer
Zack Crane
Katelyn Chando
Sylvie Asselin
Weidong Liu
Mike Welch
Adam Cook
David A Moreno
Tony P Tang
Original Assignee
Array Biopharma Inc
Loxo Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc, Loxo Oncology Inc filed Critical Array Biopharma Inc
Publication of UY37927A publication Critical patent/UY37927A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

En algunas formas de realización, en la presente se provee un proceso para preparar un compuesto de Fórmula I o una sal farmacéuticamente aceptable del mismo, como se divulga en la presente.
UY0001037927A 2017-10-10 2018-10-10 Proceso para la preparación de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo UY37927A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762570565P 2017-10-10 2017-10-10

Publications (1)

Publication Number Publication Date
UY37927A true UY37927A (es) 2019-04-30

Family

ID=64051741

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037927A UY37927A (es) 2017-10-10 2018-10-10 Proceso para la preparación de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo

Country Status (10)

Country Link
US (3) US10745419B2 (es)
EP (1) EP3694853B1 (es)
JP (1) JP6926329B2 (es)
CN (1) CN111263760B (es)
AR (1) AR113758A1 (es)
CA (1) CA3079019C (es)
ES (1) ES2949265T3 (es)
TW (1) TWI783057B (es)
UY (1) UY37927A (es)
WO (1) WO2019075092A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI783057B (zh) * 2017-10-10 2022-11-11 美商絡速藥業公司 製備6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈的方法
TWI791053B (zh) * 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
EP3845531A4 (en) * 2018-09-30 2021-11-24 Applied Pharmaceutical Science, Inc. SUBSTITUTED PYRAZOLE-CONDENSED RING DERIVATIVES, METHOD FOR THEIR PRODUCTION AND USE THEREOF
EP3980425A1 (en) * 2019-06-10 2022-04-13 JS InnoPharm (Shanghai) Ltd. Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
CN112939967B (zh) * 2019-12-11 2024-08-27 深圳众格生物科技有限公司 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用
CN111057075B (zh) * 2019-12-24 2021-04-27 武汉九州钰民医药科技有限公司 Ret抑制剂及其制备方法
CN111004257B (zh) * 2019-12-24 2021-06-29 武汉九州钰民医药科技有限公司 制备RET抑制剂Selpercatinib的方法
CN113121524B (zh) 2019-12-31 2023-04-25 南京创济生物医药有限公司 杂环亚砜亚胺化合物及其中间体、制备方法和应用
NL2024731B1 (en) 2020-01-22 2021-09-09 Sonova Ag Acoustic device with deformable shape as valve
NL2024842B1 (en) 2020-02-05 2021-09-13 Sonova Ag Acoustic device with sma microspring switch
CN111302945B (zh) * 2020-02-21 2023-06-13 上海再启生物技术有限公司 3-羟基-4-甲氧基-2-硝基苯甲酸的制备方法
CN111410662B (zh) * 2020-03-27 2020-12-29 苏州信诺维医药科技有限公司 一种酪氨酸激酶抑制剂
AR121800A1 (es) * 2020-04-17 2022-07-13 Loxo Oncology Inc Inhibidor de ret cristalino
TWI865765B (zh) * 2020-04-17 2024-12-11 美商絡速藥業公司 結晶ret抑制劑
CN113880865A (zh) * 2020-07-01 2022-01-04 上海艾力斯医药科技股份有限公司 吡唑[1,5-a]吡啶类化合物及其制备方法与应用
WO2022020279A1 (en) 2020-07-21 2022-01-27 Teva Pharmaceuticals International Gmbh Solid state forms of selpercatinib and process for preparation thereof
CA3188313A1 (en) 2020-08-05 2022-02-10 C4 Therapeutics, Inc. Compounds for targeted degradation of ret
CN114315824B (zh) * 2020-09-29 2025-03-07 南京药石科技股份有限公司 一种6-溴-4-甲氧基吡唑并[1,5-a]吡啶-3-甲腈的制备方法
US20230406865A1 (en) * 2020-11-13 2023-12-21 Shanghai Hansoh Biomedical Co., Ltd. Crystal form of free base of inhibitor containing bicyclic ring derivative and preparation method and application of crystal form
CN114621256A (zh) * 2020-12-11 2022-06-14 深圳众格生物科技有限公司 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用
CN112679494B (zh) * 2020-12-24 2023-05-16 贵州民族大学 一种吡唑并[1,5-a]吡啶衍生物的制备方法
WO2022168122A1 (en) * 2021-02-06 2022-08-11 Msn Laboratories Private Limited, R&D Center Processes for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
CN113321668A (zh) * 2021-06-21 2021-08-31 江苏慧聚药业有限公司 塞尔帕替尼的合成
CN113387947B (zh) * 2021-07-12 2022-07-01 中国科学院成都生物研究所 调节雌激素受体合成活性的吡唑并吡啶衍生物
MX2024007017A (es) * 2021-12-13 2024-06-19 Loxo Oncology Inc Procesos para la preparacion de la forma cristalina a de selpercatinib. un inhibidor ret.
CN117229292B (zh) * 2022-10-18 2025-08-15 药雅科技(上海)有限公司 Ret抑制剂的制备及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086042A1 (es) * 2011-04-28 2013-11-13 Galapagos Nv Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica
CN102827073A (zh) * 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
TW201443037A (zh) * 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
JP6816100B2 (ja) * 2015-07-16 2021-01-20 アレイ バイオファーマ、インコーポレイテッド ＲＥＴキナーゼ阻害物質としての置換ピラゾロ［１，５−ａ］ピリジン化合物
TWI704148B (zh) * 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI783057B (zh) * 2017-10-10 2022-11-11 美商絡速藥業公司 製備6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈的方法

Also Published As

Publication number Publication date
TW201922757A (zh) 2019-06-16
CA3079019C (en) 2022-07-19
US20210380609A1 (en) 2021-12-09
ES2949265T3 (es) 2023-09-27
WO2019075092A1 (en) 2019-04-18
US20190106438A1 (en) 2019-04-11
US11807651B2 (en) 2023-11-07
AR113758A1 (es) 2020-06-10
EP3694853B1 (en) 2023-05-17
US10745419B2 (en) 2020-08-18
CN111263760A (zh) 2020-06-09
US20200308194A1 (en) 2020-10-01
CN111263760B (zh) 2023-06-23
JP2020536084A (ja) 2020-12-10
US11098064B2 (en) 2021-08-24
TWI783057B (zh) 2022-11-11
CA3079019A1 (en) 2019-04-18
JP6926329B2 (ja) 2021-08-25
EP3694853A1 (en) 2020-08-19

Similar Documents

Publication Publication Date Title
UY37927A (es) Proceso para la preparación de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo
CL2020000886A1 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih.
CL2017000379A1 (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7)
MX2020007265A (es) Derivados de rapamicina.
MX375970B (es) Compuestos de triazolopirimidina y usos de los mismos.
MX2021014128A (es) Polimorfos de selinexor.
NZ735575A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
NZ732391A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EA201791304A1 (ru) Производные изохинолина для лечения вич
MX2018000280A (es) Oxiesteroles y metodos de uso de los mismos.
PH12015502443A1 (en) 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
BR112017001565A2 (pt) ?composto, métodos para tratar uma infecção e para fabricar um medicamento, composição farmacêutica, e, uso de um composto?
CO6700837A2 (es) Proceso de elaboración para derivados de prrimidina
AR103680A1 (es) Inhibidores selectivos de bace1
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
MX388321B (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
HK1211290A1 (en) Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
MX374300B (es) Sal de trifluoroacetato de agonista de tlr7 y forma cristalina b de la misma, métodos de preparación y usos.
MX376283B (es) Compuestos de imidazopiridazina.
BR112017003242A2 (pt) composto, métodos para tratar infecção por vírus e para fabricação de um medicamento, composição farmacêutica, e, uso de um composto.
CR20160016A (es) Pirazolpiridinas sustituidas
WO2015110491A3 (en) Pyrazolo[1,5-a]pyrimidines as antiviral compounds

Legal Events

Date Code Title Description
105 Application deemed to be withdrawn (no grant fee paid)

Effective date: 20250408